Moreover, the expression of PD-L1 can be upregulated by IFN-γ, and the absence of IFN-γ signaling pathway in tumor cells leads to the resistance to CTLA-4 targeting therapy, so that IFN-γ is a novel biomarker to predict the response to ICIs (73, 74). This evidence concerns the gene CTLA4 and neoplasm.